Boehringer And Anthem Put Stiolto Duo To Real World Test In COPD
US noninferiority study mainly of Anthem beneficiaries aims to show if COPD patients are being overtreated with LABA/LAMA/ICS triple combos when a LABA/LAMA duo would do.
You may also be interested in...
New guidelines for the treatment of COPD could change the way this serious condition is managed, with knock-on effects for pharma companies with respiratory franchises.
The Salford Lung Study is pioneering in the emerging field of gathering real-world evidence. David Leather, Global Medical Affairs Leader in the Respiratory Franchise at GSK, led the UK-based study and talked to the Pink Sheet about why it was important for GSK and what may come next.
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.